- Oops!Something went wrong.Please try again later.
LOS ANGELES, CA / ACCESSWIRE / December 20, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zynerba Pharmaceuticals, Inc. ("Zynerba" or "the Company") (NASDAQ:ZYNE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between March 11, 2019 and September 17, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before December 23, 2019.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at firstname.lastname@example.org.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Zynerba's Zygel treatment was not well-tolerated nor particularly safe in the BELIEVE 1 Trial. This put the Company at risk of not securing regulatory approval for Zygel. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Zynerba, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
SOURCE: The Schall Law Firm
View source version on accesswire.com: